Jun 22, 2021 Efficacy, Safety, and Tolerability of Seladelpar in Patients With Compensated Liver Cirrhosis Due to Primary Biliary Cholangitis
Jun 22, 2021 An Independent Blinded Review of Suspected Drug Induced Liver Injury In NASH Patients by a Panel of Pathologists and Hepatologists
Mar 11, 2021 Quantitative assessment of NASH pathologies in 152 baseline H&E slides from a Phase 2 trial using the Path AI machine learning algorithm
Nov 13, 2020 A 52-Week Multi-Center Double-Blind Randomized Phase 2 Study of Seladelpar, a Potent and Selective Peroxisome Proliferator-Activated Receptor Delta (PPAR) Agonist, in Patients with Nonalcoholic Steatohepatitis (NASH)
Aug 27, 2020 Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study
Aug 27, 2020 The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice
